Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dosage form

A dosage form and agonist technology, which is applied in the field of preparation of the dosage form and anti-interference dosage form, can solve the problems such as not easy to be crushed, large nasal administration, difficult to separate, etc.

Inactive Publication Date: 2013-09-04
EURO-CELTIQUE SA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The composition and size of the drug-containing particles provide resistance to crushing, so that even though the matrix is ​​a crushable material, the totality available is particles that are difficult to separate and too small to be crushed further but are useful for nasal administration. too big for medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dosage form
  • Dosage form
  • Dosage form

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0086] Drugs included in the preparation of dosage forms of the invention preferably have an average particle size of less than 500 microns, more preferably less than 300 microns, still more preferably less than 200 or 100 microns. There is no lower limit to the average particle size and may for example be below 50 microns, such as below 40 microns, below 30 microns, below 20 microns or even below 10 microns. The particle size of the drug can be determined by any conventional technique in the art, such as laser light scattering, sieve analysis, light microscopy or image analysis. In general, it is preferred that the largest dimension of the drug particle is smaller than the size of the granule (eg, smaller than the smallest dimension of the granule). It is also considered generally advantageous to utilize drug particles and non-melting and / or non-softening and / or non-dissolving excipients whose particle size is at least half the diameter of the molten extrudate and which In t...

Embodiment 1

[0217] Granules with the composition outlined in Table 1 were prepared as follows:

[0218]

[0219] *10% based on ethyl cellulose

[0220] **20% based on ethyl cellulose

[0221] The ethyl cellulose / triethyl citrate formulation is initially prepared by placing the ethyl cellulose in a mixer and adding the triethyl citrate gradually, for example by spraying. Mixing was continued until a homogeneous blend was obtained, then the mixture was allowed to stand overnight to allow the triethyl citrate to penetrate through the ethyl cellulose.

[0222] Hydromorphone hydrochloride, naloxone hydrochloride, stearyl alcohol, glyceryl dibehenate, and the ethylcellulose / triethyl citrate formulation prepared above were then added to the mixer and mixed. The resulting mixture is used The aqueous dispersion of NE 40D was granulated and the granules were subsequently dried to constant weight.

[0223] The dried granules are subsequently extruded. The melt extruder is set to predetermin...

Embodiment 2

[0230] Melt-extruded granules having the composition outlined in Table 3 below were prepared by first preparing placebo granules (by fluid bed granulation) having the composition outlined in Table 4 below, and secondly milling the placebo granules (using a 0.5 mm sieve Retsch mill), and third, blend the ground placebo granules with hydromorphone hydrochloride, naloxone hydrochloride, and magnesium stearate in an appropriately sized conical mixer to produce blended granules , and finally, the blended pellets were melt-extruded in a Leistritz Micro27 melt extruder to obtain extrudates, which were stretched and finally cut with a pelletizer to obtain melt-extruded pellets.

[0231] The particles obtained had an average diameter of 0.80 mm and an average length of 0.84 mm.

[0232] table 3

[0233]

[0234] S = solid content

[0235] Table 4

[0236]

[0237] S = solid content

[0238] Tablets with the composition outlined in Table 5 below were prepared by blending the g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
lengthaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix.

Description

field of invention [0001] The present invention relates to dosage forms, especially tamper-resistant dosage forms, comprising melt-extruded particles and matrices comprising a drug, and methods of making said dosage forms. The invention also relates to the use of said dosage form in medicine, eg in the treatment of pain. Background of the invention [0002] There is a general desire to provide pharmaceuticals in an anti-interference form to maximize the chance of their utilization in the desired manner. This in turn ensures that the drug may have the desired full pharmacological effect. Even more importantly, delivering drugs in an anti-interference form means they are harder to abuse. [0003] Medicines that contain certain types of drugs may of course be more likely to be abused than others. For example, dosage forms (e.g., tablets) containing an opioid agonist, tranquilizer, CNS depressant, CNS stimulant, or sedative hypnotic are often Targets for abuse, especially do...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K9/20A61P25/04A61K31/485
CPCA61K9/1635A61K9/1652A61K9/1682A61K9/2027A61K9/2054A61K9/2077A61K9/2095A61K31/485A61K45/00A61K9/2031A61K9/205A61K9/5084A61K31/00A61P25/00A61P25/04A61K9/20A61K9/16A61J3/00A61K9/00B29B9/12
Inventor 哈桑·穆罕默德
Owner EURO-CELTIQUE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com